Skip to main content

Advertisement

Log in

Long-term Analysis of Gemcitabine-based Chemoradiation after Surgical Resection for Pancreatic Adenocarcinoma

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the efficacy in terms of local control (LC) of 24 h infusion of gemcitabine plus radiotherapy after surgery for pancreatic cancer.

Methods

Weekly gemcitabine (100 mg/m2) was provided as a 24-hour infusion during the course of radiotherapy (50.4 Gy to the tumor, 39.6 Gy to the nodes). Patients subsequently received five cycles of gemcitabine monochemotherapy (1,000 mg/m2 1, 8, q21). The primary end point of the study was to achieve a 2-year LC rate of ≥80 % with type I and II errors of 5 and 20 %. The study was designed to accrue a maximum sample size of 35 patients. Secondary end points were toxicity evaluation, metastasis-free survival (MFS), and overall survival (OS).

Results

Data of 35 patients were available. Most of the patients (n = 27; 77.1 %) had duodeno-cephalo-pancreatectomy, 5 (14.3 %) distal pancreatectomy, and 3 (8.6 %) total pancreatectomy. The pathological stages were T1–T2 (n = 7; 20.0 %), T3–T4 (n = 28; 80.0 %), N0 (n = 17; 48.6 %), and N1 (n = 18; 51.4 %). Thirty patients (85.7 %) completed chemoradiation. Twenty-three patients (65.7 %) received further sequential chemotherapy. Acute toxicity was acceptable. No late toxicity occurred. The median follow-up period was 64 (range 24–118) months, and 2-year crude rate of LC was 83 (median not reached). Median MFS and OS were 26.5 and 22.5 months, respectively.

Conclusions

The rate of LC met the main goal of the study. The regimen resulted in a high LC rate but failed to show a benefit in terms of OS or MFS, thus suggesting the need for a more intensified multimodal approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Cancer. 1987;60:2284–303.

    Article  PubMed  CAS  Google Scholar 

  2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1996;46:5–27.

    Article  PubMed  CAS  Google Scholar 

  3. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinomas of the pancreas: 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.

    Article  PubMed  CAS  Google Scholar 

  4. Kalser M, Ellenberg S. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899–903.

    Article  PubMed  CAS  Google Scholar 

  5. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg. 1999;230:776–82.

    Article  PubMed  CAS  Google Scholar 

  6. Garofalo M, Flannery T, Regine W. The case for adjuvant chemoradiation for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:403–16.

    Article  PubMed  CAS  Google Scholar 

  7. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.

    Article  PubMed  CAS  Google Scholar 

  8. Hazard L. The role of radiation therapy in pancreatic cancer. Gastrointest Cancer Res. 2009;3:20–8.

    PubMed  Google Scholar 

  9. Haller D. Chemotherapy for advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2003;56:16–23.

    Article  PubMed  CAS  Google Scholar 

  10. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–81.

    Article  PubMed  CAS  Google Scholar 

  11. Shewach DS, Lawrence TS. Radiosensitization of human tumor cells by gemcitabine in vitro. Semin Oncol. 1995;22(Suppl 11):68–71.

    PubMed  CAS  Google Scholar 

  12. Mohiuddin M, Kudrimoti M, Regine WF, McGrath PC, Hanna N, John W. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: a phase I study. Cancer J. 2002;8:255–62.

    Article  PubMed  Google Scholar 

  13. Mattiucci GC, Morganti AG, Valentini V, et al. External beam radiotherapy plus 24-hour continuous infusion of gemcitabine in unresectable pancreatic carcinoma: long-term results of a phase II study. Int J Radiat Oncol Biol Phys. 2010;76:831–8.

    Article  PubMed  CAS  Google Scholar 

  14. Oken MM, Creech RH, Thormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.

    Article  PubMed  CAS  Google Scholar 

  15. Kaplan FL, Meier P. Non parametric estimation from incomplete observations. Am J Stat Assoc. 1958;53:457–81.

    Article  Google Scholar 

  16. Peto R, Peto J. Asymptomatically efficient rank invariant procedures. J R Stat Soc. 1972;135:185–207.

    Google Scholar 

  17. Cox DR. Regression model and life tables. J R Stat Soc Ser B. 1972;34:187–220.

    Google Scholar 

  18. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019–26.

    Article  PubMed  CAS  Google Scholar 

  19. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curtive-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.

    Article  PubMed  CAS  Google Scholar 

  20. Demols A, Peeters M, Polus M, et al. Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian phase II study. Int J Radiat Oncol Biol Phys. 2005;62:1351–6.

    Article  PubMed  CAS  Google Scholar 

  21. Van Laethem JL, Demols A, Gay F, et al. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study. Int J Radiat Oncol Biol Phys. 2003;56:974–80.

    Article  PubMed  Google Scholar 

  22. Blackstock AW, Mornex F, Partensky C, et al. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer. 2006;95:260–5.

    Article  PubMed  CAS  Google Scholar 

  23. Van Laethem JL, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010;28:4450–6.

    Article  PubMed  Google Scholar 

  24. Huguet F, André T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25:326–31.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Edy Ippolito MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mattiucci, G.C., Ippolito, E., D’Agostino, G.R. et al. Long-term Analysis of Gemcitabine-based Chemoradiation after Surgical Resection for Pancreatic Adenocarcinoma. Ann Surg Oncol 20, 423–429 (2013). https://doi.org/10.1245/s10434-012-2767-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-012-2767-7

Keywords

Navigation